The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Systemic mastocytosis: current treatments and emerging targeted agents
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the treatment of patients with advanced, indolent and smoldering systemic mastocytosis (SM), covering anti-mediator and cytotoxic treatments, before highlighting the development of targeted agents. Dr Bose describes the high potency and selectivity of avapritinib and bezuclastinib against mutated KIT kinase, and comments on promising efficacy and safety results from ongoing trials. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
